Safety, Efficacy, and Patient-Reported Outcomes of Venetoclax in Combination With Azacitidine for the Treatment of Patients With Higher-Risk Myelodysplastic Syndrome: A Phase 1b Study

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2021年 / 19卷 / 01期
关键词：
LEUKEMIA;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：14 / 16
页数：3
相关论文
共 50 条
  • [31] Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
    Chien, Kelly S.
    Borthakur, Gautam M.
    Naqvi, Kiran
    Daver, Naval G.
    Cortes, Jorge E.
    DiNardo, Courtney D.
    Jabbour, Elias
    Andreeff, Michael
    Alvarado, Yesid
    Bose, Prithviraj
    Jain, Nitin
    Sheppard, Kimberly
    Klingner-Winton, Cheri
    Pierce, Sherry A.
    Dong, Xiao Qin
    Soltysiak, Kelly
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2019, 134
  • [32] Efficacy and safety analysis of venetoclax combined with hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes in the real world
    高清妍
    China Medical Abstracts(Internal Medicine), 2024, 41 (03) : 186
  • [33] Phase 2, Randomized, Double-Blind Study of Pracinostat in Combination With Azacitidine in Patients With Untreated, Higher-Risk Myelodysplastic Syndromes
    Garcia-Manero, Guillermo
    Montalban-Bravo, Guillermo
    Berdeja, Jesus G.
    Abaza, Yasmin
    Jabbour, Elias
    Essell, James
    Lyons, Roger M.
    Ravandi, Farhad
    Maris, Michael
    Heller, Brian
    DeZern, Amy E.
    Babu, Sunil
    Wright, David
    Anz, Bertrand
    Boccia, Ralph
    Komrokji, Rami S.
    Kuriakose, Philip
    Reeves, James
    Sekeres, Mikkael A.
    Kantarjian, Hagop M.
    Ghalie, Richard
    Roboz, Gail J.
    CANCER, 2017, 123 (06) : 994 - 1002
  • [34] Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
    Sekeres, Mikkael A.
    Komrokji, Rami S.
    Lancet, Jeffrey E.
    Tiu, Ramon V.
    Advani, Anjali S.
    Afable, Manual
    Englehaupt, Ricki
    Juersivich, Joyce
    Cuthbertson, David
    Paleveda, Jennifer
    Paquette, Ronald
    Smith, April
    Strozniak, Lori
    List, Alan F.
    Maciejewski, Jaroslaw P.
    BLOOD, 2011, 118 (21) : 279 - 279
  • [35] A Phase II Study of Clinical Efficacy of Venetoclax in Combination with Azacitidine in Patients with Therapy Related Myelodysplastic Syndrome (t-MDS)
    Borate, Uma M.
    Dvorak-Kornaus, Kaitlyn M.
    Zhao, Qiuhong
    Koenig, Kristin L.
    Eisfeld, Ann-Kathrin
    Madanat, Yazan F.
    BLOOD, 2023, 142
  • [36] PHASE 1B STUDY OF GLASDEGIB (PF-04449913) IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH HIGHER RISK MYELODYSPLASTIC SYNDROME, OLIGOBLASTIC ACUTE MYELOID LEUKEMIA, OR CHRONIC MYELOMONOCYTIC LEUKEMIA
    Borate, U.
    Smith, B. D.
    Gore, S.
    Zeidan, A.
    Savona, M.
    Savoie, M. L.
    Zhu, N.
    Breems, D.
    Zhang, X.
    Shaik, M. N.
    Rampersad, A.
    Chan, G.
    Woolfson, A.
    Sekeres, M.
    HAEMATOLOGICA, 2016, 101 : 73 - 74
  • [37] Efficacy and Safety of Pevonedistat Plus Azacitidine Vs Azacitidine Alone in Higher-Risk Myelodysplastic Syndromes From Study P-2001
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 11 - 13
  • [38] Phase 2 Expansion Study of Oral Rigosertib Combined With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Efficacy and Safety Results in HMA Treatment-Naive and Relapsed/Refractory Patients
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 8 - 9
  • [39] A Phase 1b Study of Eltrombopag and Azacitidine in Patients with High Risk Myelodysplastic Syndromes and Related Disorders
    Sternberg, Alex
    Boucher, Rebecca H.
    Coulthard, Helen C.
    Raghavan, Manoj
    Culligan, Dominic J.
    Jackson, Aimee
    Cargo, Catherine
    Dennis, Mike
    Metzner, Marlen
    Moore, Rachel
    Bowen, David
    Vyas, Paresh
    BLOOD, 2020, 136
  • [40] Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromes
    Garcia, Jacqueline S.
    Platzbecker, Uwe
    Odenike, Olatoyosi
    Fleming, Shaun
    Fong, Chun Yew
    Borate, Uma
    Jacoby, Meagan A.
    Nowak, Daniel
    Baer, Maria R.
    Peterlin, Pierre
    Chyla, Brenda
    Wang, Huipei
    Ku, Grace
    Hoffman, David
    Potluri, Jalaja
    Garcia-Manero, Guillermo
    BLOOD, 2025, 145 (11) : 1126 - 1135
12345